Your browser doesn't support javascript.
loading
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.
Pietarinen, P O; Pemovska, T; Kontro, M; Yadav, B; Mpindi, J P; Andersson, E I; Majumder, M M; Kuusanmäki, H; Koskenvesa, P; Kallioniemi, O; Wennerberg, K; Heckman, C A; Mustjoki, S; Porkka, K.
Afiliação
  • Pietarinen PO; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Pemovska T; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Kontro M; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Yadav B; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Mpindi JP; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Andersson EI; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Majumder MM; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Kuusanmäki H; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Koskenvesa P; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Kallioniemi O; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Wennerberg K; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Heckman CA; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  • Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Porkka K; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Blood Cancer J ; 5: e309, 2015 May 01.
Article em En | MEDLINE | ID: mdl-25933373
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Crise Blástica / Sobrevivência Celular / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Blood Cancer J Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Crise Blástica / Sobrevivência Celular / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Blood Cancer J Ano de publicação: 2015 Tipo de documento: Article